Prof. Dr. med. Alexandar Tzankov Faculty of Medicine OverviewResearch Publications Projects & Collaborations Projects & Collaborations OverviewResearch Publications Projects & Collaborations Profiles & Affiliations Projects & Collaborations 9 foundShow per page10 10 20 50 P2_ SARS-CoV-2_interactions_Basel-region_cohort Research Project | 1 Project MembersNo Description available Genetic background and genomic evolution of relapsing classical Hodgkin lymphoma Research Project | 1 Project MembersNo Description available Role of the bone marrow niche in breast cancer metastasis and therapy response Research Project | 1 Project MembersNo Description available Die Rolle von GATA1 in der fötalen Hämatopoiese bei Trisomie 21 Research Project | 1 Project MembersNo Description available Preclinical and clinical phase 1 testing of anti-microtubular agent (BAL101553) in cancer cells, tumor samples and translational detection of predictive biomarkers Research Project | 1 Project MembersNo Description available Clonal Relationship in Composite Mantle Cell- and Follicular-, Small Lymphocytic and Plasmacytic Lymphoma Research Project | 1 Project MembersNo Description available Rolle von Cbl-b bei der T-Zellaktivierung Research Project | 1 Project MembersNo Description available Clinical Impact of Genetic Pathway Defects on Rituxan (Rituximab)-CHOP therapy in Patients with Diffuse Large B-cell Lymphoma Research Project | 1 Project MembersDiffuse large B cell lymphoma (DLBCL) is the most common lymphoid malignancy, comprising approximately 30% of all adult lymphomas, with a rapidly rising incidence [Fisher & Fisher 2006; Mitterlechner et al. 2006; Stein et al. 2008]. DLBCL demonstrate an aggressive clinical course that requires aggressive therapy, but only about 40% of patients can be cured by cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or equivalent regimens [Coiffier 2005 & 2007]. The demonstration of the activity of the monoclonal anti-CD20 antibody rituximab (R) in phase II and III studies [Coiffier et al. 2002] has established R-CHOP as the new standard of DLBCL treatment, potentially curing 60% of patients [Sehn et al. 2005; Pfreundschuh et al. 2006; Coiffier 2007]. Prior to R-CHOP, prediction of survival and stratification of patients for risk-adjusted therapy was based on the international prognostic index (IPI) [Shipp et al. 1993], which consists of five easily assessable, predominantly patient-related, clinical and laboratory parameters: age, serum lactate dehydrogenase, stage, performance status and >1 extranodal sites involved. R-CHOP has not only led to a marked improvement in DLBLC survival, but has also called into question the significance of IPI [Sehn et al. 2007], leading to the introduction of the revised IPI (R-IPI). Importantly, preliminary data suggest that IPI and R-IPI can no longer identify DLBCL risk-groups with <50% chance of survival, although about 40% of patients will still die of/with disease. Thus, there is an urgent need for identification of additional, particularly tumor-related, prognostic and predictive factors in DLBCL. Structural and numerical aberrations of the oncogenes MYC, BCL2 and BCL6 as well as of the tumor suppressor p53 are reliably assessable on paraffin-embedded lymphoma tissue samples [e.g. Obermann et al. 2009a & b; Tibiletti et al. 2009; Tzankov et al. 2009]. Their prognostic role in DLBCL has been postulated in CHOP treated collectives (see Appendix 5.4.1.), but little is known on their prognostic and predictive role in R-CHOP treated cases. The aim of the present study will be to clarify the prognostic and predictive importance of the gene status of MYC, BCL2, BCL6 and p53 on over 800 DLBCL cases treated with R-CHOP with respect to other clinical and phenotypic features, especially DLBCL histogenesis from germinal center- (GC) or non-/post-GC B cells [Alizadeh et al. 2000; Hans et al. 2004]. Altersspezifischer Unterschiede der Zusammensetzung der Knochenmarkslymphozyten Research Project | 1 Project MembersNo Description available 1 1 OverviewResearch Publications Projects & Collaborations
Projects & Collaborations 9 foundShow per page10 10 20 50 P2_ SARS-CoV-2_interactions_Basel-region_cohort Research Project | 1 Project MembersNo Description available Genetic background and genomic evolution of relapsing classical Hodgkin lymphoma Research Project | 1 Project MembersNo Description available Role of the bone marrow niche in breast cancer metastasis and therapy response Research Project | 1 Project MembersNo Description available Die Rolle von GATA1 in der fötalen Hämatopoiese bei Trisomie 21 Research Project | 1 Project MembersNo Description available Preclinical and clinical phase 1 testing of anti-microtubular agent (BAL101553) in cancer cells, tumor samples and translational detection of predictive biomarkers Research Project | 1 Project MembersNo Description available Clonal Relationship in Composite Mantle Cell- and Follicular-, Small Lymphocytic and Plasmacytic Lymphoma Research Project | 1 Project MembersNo Description available Rolle von Cbl-b bei der T-Zellaktivierung Research Project | 1 Project MembersNo Description available Clinical Impact of Genetic Pathway Defects on Rituxan (Rituximab)-CHOP therapy in Patients with Diffuse Large B-cell Lymphoma Research Project | 1 Project MembersDiffuse large B cell lymphoma (DLBCL) is the most common lymphoid malignancy, comprising approximately 30% of all adult lymphomas, with a rapidly rising incidence [Fisher & Fisher 2006; Mitterlechner et al. 2006; Stein et al. 2008]. DLBCL demonstrate an aggressive clinical course that requires aggressive therapy, but only about 40% of patients can be cured by cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or equivalent regimens [Coiffier 2005 & 2007]. The demonstration of the activity of the monoclonal anti-CD20 antibody rituximab (R) in phase II and III studies [Coiffier et al. 2002] has established R-CHOP as the new standard of DLBCL treatment, potentially curing 60% of patients [Sehn et al. 2005; Pfreundschuh et al. 2006; Coiffier 2007]. Prior to R-CHOP, prediction of survival and stratification of patients for risk-adjusted therapy was based on the international prognostic index (IPI) [Shipp et al. 1993], which consists of five easily assessable, predominantly patient-related, clinical and laboratory parameters: age, serum lactate dehydrogenase, stage, performance status and >1 extranodal sites involved. R-CHOP has not only led to a marked improvement in DLBLC survival, but has also called into question the significance of IPI [Sehn et al. 2007], leading to the introduction of the revised IPI (R-IPI). Importantly, preliminary data suggest that IPI and R-IPI can no longer identify DLBCL risk-groups with <50% chance of survival, although about 40% of patients will still die of/with disease. Thus, there is an urgent need for identification of additional, particularly tumor-related, prognostic and predictive factors in DLBCL. Structural and numerical aberrations of the oncogenes MYC, BCL2 and BCL6 as well as of the tumor suppressor p53 are reliably assessable on paraffin-embedded lymphoma tissue samples [e.g. Obermann et al. 2009a & b; Tibiletti et al. 2009; Tzankov et al. 2009]. Their prognostic role in DLBCL has been postulated in CHOP treated collectives (see Appendix 5.4.1.), but little is known on their prognostic and predictive role in R-CHOP treated cases. The aim of the present study will be to clarify the prognostic and predictive importance of the gene status of MYC, BCL2, BCL6 and p53 on over 800 DLBCL cases treated with R-CHOP with respect to other clinical and phenotypic features, especially DLBCL histogenesis from germinal center- (GC) or non-/post-GC B cells [Alizadeh et al. 2000; Hans et al. 2004]. Altersspezifischer Unterschiede der Zusammensetzung der Knochenmarkslymphozyten Research Project | 1 Project MembersNo Description available 1 1
P2_ SARS-CoV-2_interactions_Basel-region_cohort Research Project | 1 Project MembersNo Description available
Genetic background and genomic evolution of relapsing classical Hodgkin lymphoma Research Project | 1 Project MembersNo Description available
Role of the bone marrow niche in breast cancer metastasis and therapy response Research Project | 1 Project MembersNo Description available
Die Rolle von GATA1 in der fötalen Hämatopoiese bei Trisomie 21 Research Project | 1 Project MembersNo Description available
Preclinical and clinical phase 1 testing of anti-microtubular agent (BAL101553) in cancer cells, tumor samples and translational detection of predictive biomarkers Research Project | 1 Project MembersNo Description available
Clonal Relationship in Composite Mantle Cell- and Follicular-, Small Lymphocytic and Plasmacytic Lymphoma Research Project | 1 Project MembersNo Description available
Rolle von Cbl-b bei der T-Zellaktivierung Research Project | 1 Project MembersNo Description available
Clinical Impact of Genetic Pathway Defects on Rituxan (Rituximab)-CHOP therapy in Patients with Diffuse Large B-cell Lymphoma Research Project | 1 Project MembersDiffuse large B cell lymphoma (DLBCL) is the most common lymphoid malignancy, comprising approximately 30% of all adult lymphomas, with a rapidly rising incidence [Fisher & Fisher 2006; Mitterlechner et al. 2006; Stein et al. 2008]. DLBCL demonstrate an aggressive clinical course that requires aggressive therapy, but only about 40% of patients can be cured by cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or equivalent regimens [Coiffier 2005 & 2007]. The demonstration of the activity of the monoclonal anti-CD20 antibody rituximab (R) in phase II and III studies [Coiffier et al. 2002] has established R-CHOP as the new standard of DLBCL treatment, potentially curing 60% of patients [Sehn et al. 2005; Pfreundschuh et al. 2006; Coiffier 2007]. Prior to R-CHOP, prediction of survival and stratification of patients for risk-adjusted therapy was based on the international prognostic index (IPI) [Shipp et al. 1993], which consists of five easily assessable, predominantly patient-related, clinical and laboratory parameters: age, serum lactate dehydrogenase, stage, performance status and >1 extranodal sites involved. R-CHOP has not only led to a marked improvement in DLBLC survival, but has also called into question the significance of IPI [Sehn et al. 2007], leading to the introduction of the revised IPI (R-IPI). Importantly, preliminary data suggest that IPI and R-IPI can no longer identify DLBCL risk-groups with <50% chance of survival, although about 40% of patients will still die of/with disease. Thus, there is an urgent need for identification of additional, particularly tumor-related, prognostic and predictive factors in DLBCL. Structural and numerical aberrations of the oncogenes MYC, BCL2 and BCL6 as well as of the tumor suppressor p53 are reliably assessable on paraffin-embedded lymphoma tissue samples [e.g. Obermann et al. 2009a & b; Tibiletti et al. 2009; Tzankov et al. 2009]. Their prognostic role in DLBCL has been postulated in CHOP treated collectives (see Appendix 5.4.1.), but little is known on their prognostic and predictive role in R-CHOP treated cases. The aim of the present study will be to clarify the prognostic and predictive importance of the gene status of MYC, BCL2, BCL6 and p53 on over 800 DLBCL cases treated with R-CHOP with respect to other clinical and phenotypic features, especially DLBCL histogenesis from germinal center- (GC) or non-/post-GC B cells [Alizadeh et al. 2000; Hans et al. 2004].
Altersspezifischer Unterschiede der Zusammensetzung der Knochenmarkslymphozyten Research Project | 1 Project MembersNo Description available
